Register Now: Beyond EDC: Designing a Connected Data Strategy for Predictive Clinical Development
Blog|Slideshows|October 28, 2024

4 Perspectives on Sustainability in Clinical Research

As studies become more complex, stakeholders must be aware of the resources they are utilizing and their impact on the environment.

Sustainability in clinical research is key. As complexity and productivity in the industry continue to rise, so does the need for additional resources. According to a recent IQVIA Institute for Human Data Science report, clinical development productivity rose to its highest level since 2018.

Stakeholders must be keen on how they utilize clinical resources, even with positive trends in productivity and development. With strategic management, industry can ensure the long-term effectiveness of clinical trials and their ability to bring therapies to patients faster.

In this slideshow, Julia Sundari, senior director of clinical design and analytics, IQVIA; Michael Cohen, MSc, MBA, senior director, lead, environmental sustainability, PPD clinical research business of Thermo Fisher Scientific; Robyn Owens, manager, recruitment and engagement, PPD clinical research business of Thermo Fisher Scientific; Bill Sterling, senior director of environmental, health and safety, IQVIA Laboratories; and Bryan Spielman, chief growth officer, Advarra each share a critical component to ensuring the long-term effectiveness of clinical research.

Image Credit: © Dee karen - stock.adobe.com


Related to this article

Where the Industry Is Headed as Clinical, Operational, and Real-World Data Connect
In this video interview, Rajneesh Patil, global head of AI, digital, and innovation in clinical development at Syneos Health, describes the industry’s trajectory toward a unified intelligence orchestration environment—and explains why the future isn’t one model that knows everything, but a trusted system that brings the right evidence to the right human decision.
The Human Side of Clinical Trials: Why Fuzzy Mental Models Undermine Clinical Trial Execution
In Episode 3 of The Human Side of Clinical Trials, hosts Brian S. McGowan, PhD, FACEHP, chief learning officer and co-founder of ArcheMedX, Inc., and Kelly Ritch, chief operating officer of ArcheMedX, Inc., speak with Jason Riis, PhD, CEO and chief behavioral scientist at Behavioralize, about why a well-written protocol doesn’t always translate into consistent execution, and how designing for the way people actually think and learn can reduce site burden and the need for costly unlearning.